Search

for
Search:

Research

5 / 29 results

research An infant with congenital micrognathia and upper airway obstruction was diagnosed as Hutchinson-Gilford progeria syndrome caused by a novel LMNA mutation: Case report and literature review

1 citations , October 2023 in “Heliyon”

In this study, the researchers reported a new case of Hutchinson-Gilford progeria syndrome with a novel LMNA mutation and successful surgical intervention for airway obstruction.

research Hutchinson-Gilford progeria syndrome - A brief introduction

2 citations , June 2018 in “International Journal of Pharmacological Research”

This article reviews treatments for progeria, including aspirin, hydrotherapy, and farnesyl transferase inhibitors, but reports no new clinical results.

research Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts

32 citations , July 2017 in “Oncotarget”

This study found that intermittent treatment with FTI lonafarnib and sulforaphane may be a promising therapeutic approach for children with Hutchinson-Gilford progeria syndrome, as it improved the cellular phenotype.

research Progeria (Hutchinson-Gilford Syndrome): Literature Review and Clinical Case

1 citations , July 2022 in “Вопросы современной педиатрии”

This review discusses progeria, focusing on its pathogenesis, major symptoms, and management strategies, and includes a clinical case of a girl with the disease confirmed by genetic testing; it reports no new clinical results.

research Hutchinson-Gilford syndrome: History, causes, phenotype and research advances

June 2023 in “GSC Advanced Research and Reviews”

This review covers the history, symptoms, and treatment progress for Hutchinson-Gilford Progeria Syndrome, noting that while no cure exists, understanding its molecular mechanism may improve future treatment strategies.

View more "farnesylation inhibitors" in research →

Learn

2 / 801 results

learn fusidic acid

learn Pyrilutamide

highly targeted anti-androgen that might have minimal systemic effects

View more "farnesylation inhibitors" in learn →

Community Join

1 / 1000+ results

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 2 years ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

View more "farnesylation inhibitors" in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →